CASI Pharmaceuticals Inc. (NASDAQ:CASI) went up by 8.67% from its latest closing price compared to the recent 1-year high of $3.32. The company’s stock price has collected 16.01% of gains in the last five trading sessions. Press Release reported on 01/08/21 that CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference
Is It Worth Investing in CASI Pharmaceuticals Inc. (NASDAQ :CASI) Right Now?
Plus, the 36-month beta value for CASI is at 0.49. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for CASI Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.00, which is $0.74 above the current price. CASI currently public float of 80.59M and currently shorts hold a 2.34% ratio of that float. Today, the average trading volume of CASI was 469.34K shares.
CASI’s Market Performance
CASI stocks went up by 16.01% for the week, with a monthly jump of 21.19% and a quarterly performance of 85.23%, while its annual performance rate touched -1.21%. The volatility ratio for the week stands at 5.71% while the volatility levels for the past 30 days are set at 8.20% for CASI Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 15.01% for CASI stocks with a simple moving average of 54.94% for the last 200 days.
Analysts’ Opinion of CASI
Many brokerage firms have already submitted their reports for CASI stocks, with Oppenheimer repeating the rating for CASI by listing it as a “Outperform.” The predicted price for CASI in the upcoming period, according to Oppenheimer is $5 based on the research report published on October 23rd of the previous year 2020.
Maxim Group, on the other hand, stated in their research note that they expect to see CASI reach a price target of $4. The rating they have provided for CASI stocks is “Buy” according to the report published on September 22nd, 2016.
H.C. Wainwright gave a rating of “Buy” to CASI, setting the target price at $3 in the report published on October 29th of the previous year.
CASI Trading at 32.53% from the 50-Day Moving Average
After a stumble in the market that brought CASI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.81% of loss for the given period.
Volatility was left at 8.20%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares surge +34.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.72% upper at present.
During the last 5 trading sessions, CASI rose by +16.01%, which changed the moving average for the period of 200-days by +55.98% in comparison to the 20-day moving average, which settled at $2.88. In addition, CASI Pharmaceuticals Inc. saw 10.51% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CASI starting from Xu Weihao, who purchase 4,000 shares at the price of $2.63 back on Dec 17. After this action, Xu Weihao now owns 10,000 shares of CASI Pharmaceuticals Inc., valued at $10,537 using the latest closing price.
Xu Weihao, the Chief Financial Officer of CASI Pharmaceuticals Inc., purchase 2,000 shares at $2.44 during a trade that took place back on Dec 16, which means that Xu Weihao is holding 6,000 shares at $4,880 based on the most recent closing price.
Stock Fundamentals for CASI
Current profitability levels for the company are sitting at:
- -968.07 for the present operating margin
- -32.78 for the gross margin
The net margin for CASI Pharmaceuticals Inc. stands at -1114.31. The total capital return value is set at -38.67, while invested capital returns managed to touch -50.18. Equity return is now at value -63.00, with -43.90 for asset returns.
Based on CASI Pharmaceuticals Inc. (CASI), the company’s capital structure generated 3.02 points at debt to equity in total, while total debt to capital is 2.93. Total debt to assets is 2.14, with long-term debt to equity ratio resting at 1.40. Finally, the long-term debt to capital ratio is 1.36.
When we switch over and look at the enterprise to sales, we see a ratio of 64.17, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 6.39 and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.74.